济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600566 济川药业

已收盘 07-25 15:00:00

{"stockData":{"symbol":"600566","market":"SH","secType":"STK","nameCN":"济川药业","latestPrice":27.22,"timestamp":1753426800000,"preClose":27.38,"halted":0,"volume":5600706,"delay":0,"changeRate":-0.0058,"floatShares":916000000,"shares":922000000,"eps":2.3073,"marketStatus":"已收盘","change":-0.16,"latestTime":"07-25 15:00:00","open":27.43,"high":27.57,"low":27.18,"amount":153000000,"amplitude":0.0142,"askPrice":27.23,"askSize":73,"bidPrice":27.22,"bidSize":35,"shortable":0,"etf":0,"ttmEps":2.3073,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":27.38,"symbolType":"stock","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":30.12,"lowLimit":24.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921704160,"isCdr":false,"pbRate":1.66,"roa":"--","peRate":11.797339,"roe":"2.95%","epsLYR":2.76,"committee":-0.149343,"marketValue":25089000000,"turnoverRate":0.0061,"status":1,"floatMarketCap":24927000000},"requestUrl":"/m/hq/s/600566","defaultTab":"news","newsList":[{"id":"2553342019","title":"济川药业：完成回购 累计回购2500.6万元公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2553342019","media":"格隆汇资讯","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553342019?lang=zh_cn&edition=full","pubTime":"2025-07-21 17:18","pubTimestamp":1753089491,"startTime":"0","endTime":"0","summary":"格隆汇7月21日丨济川药业(600566.SH)公布，截至2025年7月21日，本次回购期限届满，公司完成回购，公司股份回购专用证券账户通过集中竞价交易方式累计回购公司股份914,200股，占公司当前总股本的0.10%，回购最高价格29.00元/股，最低价格为26.17元/股，回购均价27.35元/股，使用资金总额2500.6万元（不含交易费用）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721171848954ace59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721171848954ace59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600566","BK0028","BK0201","BK0188","BK0187","BK0012","BK0239","BK0077"],"gpt_icon":0},{"id":"2553425059","title":"济川药业子承父业，二代交班只剩最后一步","url":"https://stock-news.laohu8.com/highlight/detail?id=2553425059","media":"深水财经社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553425059?lang=zh_cn&edition=full","pubTime":"2025-07-21 12:22","pubTimestamp":1753071762,"startTime":"0","endTime":"0","summary":"从要约收购的细节来看，此次要约收购方为济川药业控股股东江苏济川控股集团及其一致行动人。根据济川药业报告，公司2024年实现营业收入80.17亿元，同比下降16.96%；归母净利润25.32亿元，同比下降10.32%；扣非净利润22.66亿元，同比下降15.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721132124a6b7058d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721132124a6b7058d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","600566","BK0188","BK0201","BK0187","BK0012","BK0077","BK0028"],"gpt_icon":0},{"id":"2552432274","title":"济川药业最新公告：曹飞先生要约收购结果暨股票复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2552432274","media":"证券之星","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552432274?lang=zh_cn&edition=full","pubTime":"2025-07-20 16:09","pubTimestamp":1752998953,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称，曹飞要约收购期限内，预受要约的股东账户总数为34户，预受要约股份总数共计16,300股，占公司目前股份总数的0.0018%。要约收购完成后，曹飞直接及间接控制公司516,773,660股股份，占公司总股本的56.07%。本次要约收购完成后，济川药业的股权分布仍符合上市条件，上市地位不受影响。公司股票自2025年7月21日开市起复牌。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000003694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0028","BK0187","BK0077","BK0201","BK0188","600566"],"gpt_icon":0},{"id":"2552417584","title":"每周股票复盘：济川药业（600566）要约收购期满股票停牌及现金管理进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2552417584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552417584?lang=zh_cn&edition=full","pubTime":"2025-07-20 03:29","pubTimestamp":1752953347,"startTime":"0","endTime":"0","summary":"截至2025年7月17日收盘，济川药业报收于27.6元，较上周的26.22元上涨5.26%。湖北济川药业股份有限公司关于曹飞先生要约收购期满暨股票停牌的公告。截至2025年7月17日，本次要约收购期限届满，因需进一步确认要约收购结果，公司股票于2025年7月18日停牌一个交易日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000000764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0201","BK0077","BK0028","BK0187","BK0239","BK0012","600566"],"gpt_icon":0},{"id":"2552456514","title":"刚刚！征祥医药/济川药业 1 类新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2552456514","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552456514?lang=zh_cn&edition=full","pubTime":"2025-07-18 10:43","pubTimestamp":1752806610,"startTime":"0","endTime":"0","summary":"7 月 18 日，NMPA 官网显示，济川药业联合征祥医药研发的 1 类创新药玛硒洛沙韦片（济可舒）获批上市，适用于既往健康的成人单纯性甲型和乙型流感患者的治疗，不包括存在流感相关并发症高风险的患者。相比药物相关不良事件发生率，玛硒洛沙韦40mg 组为 7.1%，80 mg 组为 9.2%，与安慰剂组的 5.6% 相近。约定授予济川药业在中国大陆地区对玛硒洛沙韦口服制剂约定的适应症享有独家推广权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718110911a4526059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718110911a4526059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159938","600566","BK0077","BK0201","BK0239","BK0012","BK0028","BK0188","BK0187"],"gpt_icon":0},{"id":"2552110288","title":"济川药业：曹飞要约收购期满 股票停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2552110288","media":"格隆汇资讯","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552110288?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:42","pubTimestamp":1752741761,"startTime":"0","endTime":"0","summary":"截至2025年7月17日，本次要约收购期限届满，因需进一步确认要约收购结果,根据《上海证券交易所股票上市规则》等有关规定，经申请，公司股票于2025年7月18日(星期五)停牌一个交易日，并将在要约收购结果公告当日复牌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171646309545ebbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171646309545ebbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0201","BK0187","BK0012","BK0188","BK0077","600566","BK0028","BK0239"],"gpt_icon":0},{"id":"2551112867","title":"中药行业盘中拉升，万邦德涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2551112867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551112867?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:15","pubTimestamp":1752642941,"startTime":"0","endTime":"0","summary":"07月16日，中药行业盘中拉升，截至13点15分，中药行业整体指数上涨1.01%，报6465.270点。从个股上来看，该行业的成分股中，万邦德涨停，济川药业、贵州百灵2只股涨幅超过5%。从资金上来看，截止发稿，中药行业主力净流入为-5783.86万，其中众生药业受到资金热捧，主力净流入8232.13万；拉长时间线来看，该板块近20日主力资金净流入-37.97亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161315419544677a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507161315419544677a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0004","BK0201","BK0028","BK0239","BK0050","BK0012","600566","002082","BK0077","BK0187"],"gpt_icon":0},{"id":"2551114281","title":"济川药业涨5.02%创近4个月新高 资金博弈与政策预期共振带动上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114281","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551114281?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:02","pubTimestamp":1752642149,"startTime":"0","endTime":"0","summary":"济川药业股价今日大幅上涨，截至13点01分，最新价为27.64元/股，涨幅达5.02%，创近4个月新高。资金博弈与政策预期共振济川药业近日股价波动与资金面及政策预期密切相关。产品迭代与估值锚点重塑济川药业长期估值中枢取决于中药产品迭代与政策博弈成效。国投证券给予29.30元目标价，对应2025年12倍动态市盈率，但需警惕新品渠道拓展不及预期风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716130237a6ac99e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716130237a6ac99e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","600566","BK0077","BK0187","BK0188","BK0201","BK0028","BK0012"],"gpt_icon":0},{"id":"2551518169","title":"济川药业：流感1类新药玛硒洛沙韦上市申请工作正在推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2551518169","media":"互动易","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551518169?lang=zh_cn&edition=full","pubTime":"2025-07-15 15:33","pubTimestamp":1752564781,"startTime":"0","endTime":"0","summary":"有投资者向济川药业提问， 网上有信息公司与征祥医药合作的流感1类新药玛赛洛沙韦片上市申请（NDA）有望于2025年上半年获国家药品监督管理局批准。请公司介绍下该新药上市进度？何时可以获批上市？公司回答表示，尊敬的投资者，您好。我方与征祥医药合作的流感1类新药玛硒洛沙韦上市申请工作正在推进中。如有重大进展或变化，公司也将严格按照相关法律法规要求，及时履行信息披露义务。感谢您的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715154555a44bb8ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715154555a44bb8ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0201","BK0187","BK0239","BK0028","BK0188","BK0077","600566"],"gpt_icon":0},{"id":"2551130680","title":"中药概念盘中跳水，济川药业跌0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551130680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551130680?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:33","pubTimestamp":1752546811,"startTime":"0","endTime":"0","summary":"07月15日，中药概念盘中跳水，截至10点33分，中药概念整体指数下跌2.02%，报1340.740点。从个股上来看，该概念的成分股中，济川药业跌0.04%，康美药业跌幅居前。从资金上来看，截止发稿，中药概念概念主力净流入为-10.18亿，其中安科生物受到资金热捧，主力净流入5902.45万；拉长时间线来看，该板块近20日主力资金净流入-80.77亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151033319542db81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507151033319542db81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600566","BK0077","BK0201","BK0239","BK0187","BK0012","BK0188","BK0028"],"gpt_icon":0},{"id":"2551916502","title":"每周股票复盘：济川药业（600566）小儿便通颗粒申报上市、复方聚乙二醇电解质散获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2551916502","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551916502?lang=zh_cn&edition=full","pubTime":"2025-07-13 02:16","pubTimestamp":1752344171,"startTime":"0","endTime":"0","summary":"截至2025年7月11日收盘，济川药业报收于26.22元，较上周的26.04元上涨0.69%。复方聚乙二醇电解质散获得药品注册证书湖北济川药业股份有限公司全资子公司济川药业集团有限公司收到国家药品监督管理局核准签发的复方聚乙二醇电解质散《药品注册证书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071300000292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0077","BK0201","BK0028","BK0239","BK0188","600566","BK0012"],"gpt_icon":0},{"id":"2550299546","title":"华创医药投资观点&研究专题周周谈第134期：中药企业的创新布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2550299546","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550299546?lang=zh_cn&edition=full","pubTime":"2025-07-12 00:00","pubTimestamp":1752249600,"startTime":"0","endTime":"0","summary":"本周，中信医药指数上涨1.80%，跑赢沪深300指数0.98个百分点，在中信30个一级行业中排名第16位。本周涨幅前十名股票为前沿生物-U、美迪西、联环药业、康辰药业、启迪药业、华纳药厂、浩欧博、塞力医疗、福瑞股份、广生堂。本周跌幅前十名股票ST未名、神州细胞、舒泰神、一品红、海辰药业、华海药业、美诺华、永安药业、荣昌生物、创新医疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712112220a445eec5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712112220a445eec5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603998","603139","600479","605199","600332","603896","600671","600252","600594","159377","600535","600436","600285","BK0239","600351","600129","399275","600572","600080","603567","600222","600993","600750","600518","603439","603858","600976","600566","600557","600771"],"gpt_icon":0},{"id":"2550536935","title":"济川药业：曹飞先生要约收购38.06%股权，价格24.85元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550536935","media":"公司公告","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550536935?lang=zh_cn&edition=full","pubTime":"2025-07-11 17:00","pubTimestamp":1752224454,"startTime":"0","endTime":"0","summary":"济川药业公告，曹飞先生自2025年6月18日起要约收购公司35084.136万股，占总股本的38.06%，要约价格为24.85元/股，支付方式为现金。本次要约收购系履行法定全面要约收购义务，不以终止公司上市地位为目的。截至2025年7月10日，预受要约股份数量为4,100股，占公司总股本比例为0.0004%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711170940a6a3736a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711170940a6a3736a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0188","BK0028","BK0077","600566","BK0239","BK0201","BK0187"],"gpt_icon":0},{"id":"2550383079","title":"济川药业子公司获复方聚乙二醇电解质散药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2550383079","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550383079?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:43","pubTimestamp":1752223416,"startTime":"0","endTime":"0","summary":"7月11日，济川药业发布公告，近日，公司全资子公司济川药业集团有限公司收到国家药品监督管理局核准签发的复方聚乙二醇电解质散《药品注册证书》。该药品注册分类为化学药品3类，适用于慢性便秘和粪便嵌塞的治疗，产品的上市许可持有人和生产企业均为济川有限。根据公告，复方聚乙二醇电解质散的批准注册将丰富公司的产品线，预计对未来发展产生积极影响。2025年一季度，济川药业实现收入15.25亿元，归母净利润4.40亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071116442697a210e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071116442697a210e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","BK0028","BK0187","BK0201","600566","BK0188","BK0012","BK0239"],"gpt_icon":0},{"id":"2550987149","title":"一周医药速览（07.07-07.11）","url":"https://stock-news.laohu8.com/highlight/detail?id=2550987149","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550987149?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:27","pubTimestamp":1752222452,"startTime":"0","endTime":"0","summary":"目前，市场上可用于小儿便秘的同类产品主要用于其他疾病伴发的便秘症状，临床尚无治疗小儿便秘的儿童专用中药创新药。甘李药业：预计上半年净利润增加100.73%到114.12%，胰岛素量价齐升甘李药业发布2025年半年度业绩预增公告。披露经财务部门初步测算，预计 2025 年半年度实现归属净利润为6亿元到6.4亿元，与上年同期相比，同比增加 100.73%到 114.12%。临床前多种动物模型研究结果显示，UBT37034与GLP-1类似物联用能显著降低体重。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711162815a44457d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711162815a44457d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603087","BK4139","06855","SVA","03933","01801","600566"],"gpt_icon":0},{"id":"2550957486","title":"1.1 类中药新药申报上市！该药企中药创新药布局再下一城","url":"https://stock-news.laohu8.com/highlight/detail?id=2550957486","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550957486?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:38","pubTimestamp":1752115096,"startTime":"0","endTime":"0","summary":"在中药创新药布局上，济川药业有着清晰且长远的战略规划。此次小儿便通颗粒上市申请获受理，无疑为济川药业在中药创新药领域的发展注入了一剂强心针。它不仅有望为广大饱受便秘困扰的儿童患者带来福音，也将进一步巩固济川药业在儿科用药领域的地位，提升公司在中药创新药市场的竞争力和影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071010395497a06531&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071010395497a06531&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159992","562390","600566","561510"],"gpt_icon":0},{"id":"2550868909","title":"中成药市场大跌！42个品牌逆势坚挺，扬子江、济川、以岭独家产品霸屏，太极猛涨79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550868909","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550868909?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:05","pubTimestamp":1752048303,"startTime":"0","endTime":"0","summary":"42个品牌销售额超过1亿元，其中独家产品占了25个，扬子江、济川、以岭、云南白药各有2个独家产品上榜。整体来看，14个品牌呈现正增长，23个品牌降幅超过10%。华润三九、太极集团、云南白药、扬子江药业各有3个品牌上榜。东阿阿胶、北京同仁堂股份、广药集团、济川药业、以岭药业、山东宏济堂制药集团各有2个品牌上榜。值得注意的是，28个品牌2025年Q1销售额有负增长，其中23个品牌降幅超过10%，危机渐渐逼近。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709161457a43fd751&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709161457a43fd751&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0201","BK0188","BK0187","BK0077","BK0012","BK0028","600129","600566"],"gpt_icon":0},{"id":"2549519746","title":"【重磅】济川药业创新研发新突破！1类新药小儿便通颗粒上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2549519746","media":"米内网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549519746?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:08","pubTimestamp":1751962113,"startTime":"0","endTime":"0","summary":"精彩内容近日，济川药业收到国家药监局签发的1.1类中药创新药小儿便通颗粒申报上市许可的《受理通知书》。据悉，济川药业将继续以“共创幸福精彩的生命体验”为愿景，秉承“引领前沿、创新精品”的研发理念，紧跟医药市场变化，从患者用药需求出发，聚焦中长期发展战略，以科研创新驱动企业高质量、可持续发展，履行好上市医药企业应有的社会责任，为大众健康护航。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708161737a43d91a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708161737a43d91a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0077","561510","BK0028","BK0187","BK0201","600566","BK0188","BK0012","BK0239","562390"],"gpt_icon":0},{"id":"2549583055","title":"济川药业：小儿便通颗粒收到药品注册申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2549583055","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549583055?lang=zh_cn&edition=full","pubTime":"2025-07-07 15:35","pubTimestamp":1751873718,"startTime":"0","endTime":"0","summary":"格隆汇7月7日丨济川药业(600566.SH)公布，全资子公司济川药业集团有限公司收到国家药品监督管理局签发的“小儿便通颗粒”申报上市许可的《受理通知书》，小儿便通颗粒来源于陈永辉医生（现首都医科大学附属首都儿童医学中心，中医科主任医师）行医多年的验方，其处方已申请专利；具有健脾和胃、行气导滞的功效，用于小儿便秘，中医辨证属食积证者。根据国家药监局网站信息显示，中国境内（不包括港澳台地区）暂无与其处方一致的药品上市或注册申报信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707153532979cbe83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707153532979cbe83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0077","BK0012","600566","BK0028","BK0187","BK0201","BK0239"],"gpt_icon":0},{"id":"2549283543","title":"每周股票复盘：济川药业（600566）回购股份及曹飞要约收购进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2549283543","media":"证券之星","labels":["shareholding","buyback","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549283543?lang=zh_cn&edition=full","pubTime":"2025-07-06 07:28","pubTimestamp":1751758091,"startTime":"0","endTime":"0","summary":"公司公告汇总湖北济川药业股份有限公司发布了关于以集中竞价交易方式回购股份的进展公告。湖北济川药业股份有限公司董事会还发布了关于曹飞要约收购事宜致全体股东的报告书。本次要约收购源于曹龙祥将其持有的济川控股10.10%股权转让给曹飞，导致曹飞间接控制济川药业56.07%股份，触发要约收购义务。本次要约收购目的系履行法定全面要约收购义务，不以终止济川药业上市地位为目的。被收购公司股票在要约收购期间正常交易。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600001073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0077","BK0188","BK0201","BK0239","600566","BK0012","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753451673441,"stockEarnings":[{"period":"1week","weight":-0.008},{"period":"1month","weight":0.062},{"period":"3month","weight":0.1529},{"period":"6month","weight":0.089},{"period":"1year","weight":-0.0492},{"period":"ytd","weight":0.0145}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":0.0541},{"period":"3month","weight":0.0943},{"period":"6month","weight":0.1086},{"period":"1year","weight":0.2425},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北济川药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41986人(较上一季度增加3.35%)","perCapita":"21810股","listingDate":"2001-08-22","address":"湖北省荆州市沙市区园林路时尚豪庭602室","registeredCapital":"92170万元","survey":"　　湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是蒲地蓝消炎口服液、小儿豉翘清热颗粒。","listedPrice":7.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"济川药业,600566,济川药业股票,济川药业股票老虎,济川药业股票老虎国际,济川药业行情,济川药业股票行情,济川药业股价,济川药业股市,济川药业股票价格,济川药业股票交易,济川药业股票购买,济川药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}